SAN DIEGO & WATERTOWN, Mass.–(BUSINESS WIRE)–Artis BioSolutions (“Artis”), an advanced therapies company dedicated to integrating the specialized technologies, infrastructure, and manufacturing capabilities required to deliver next-generation genetic medicines, today announced the establishment of new synthetic DNA manufacturing capabilities in Boston utilizing Syngoi Technologies’ (“Syngoi”) proprietary enzymatic platform. This expansion strategically extends Artis’ regional capabilities, in
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
